AbbVie Strengthens Immunology Leadership with $10.9 Billion Apogee Therapeutics Acquisition – Meet them this November

Talawar Therapeutics Heads to Nasdaq via SPAC Deal to Bankroll Eczema Asset

10 Clinical Trials to Watch Out for in the latter half of 2026 – Read here

Akero execs reunite to advance long-acting psoriasis pill

Argenx acquires Forte for $2.2B to get hands on phase 2-stage vitiligo drug

InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test

Sanofi halts development of troubled immune drug in eczema

Chasing Dupixent, a biotech aims to make better antibody drugs for eczema

Regeneron backs $75M series A for antibody upstart Infinimmune

Day

Hour

Minute

Second

Companies Attending Our 10^th Anniversary Include: AbbVie, Galderma, Merck, Eli Lilly, Sun Pharma, AOBiome, Navigator Medicines, and lots more - View the Event Guide

Robert Rissmann

Research Director CHDR

Thursday 5th November 2026

Biomarker-Driven Trials to Accelerate Early Phase Clinical Drug Development

9:30 am

Deep phenotyping of inflammatory skin diseases
Case studies of atopic dermatitis, psoriasis, urticaria and cutaneous T-cell lymphoma
Novel imaging applications in dermatology trials and application of AI